Isabelle Mourand1, Pauline Malissart2, Cyril Dargazanli3, Erika Nogue4, Stephane Bouly5, Nicolas Gaillard6, Yassine Boukriche7, Lucas Corti8, Marie-Christine Picot9, Olivier Beaufils10, Mohamed Chbicheb11, Denis Sablot12, Alain Bonafe13, Vincent Costalat14, Caroline Arquizan15. 1. Department of Neurology, CHRU, Gui de Chauliac Hospital, Montpellier, France. Electronic address: i-mourand@chu-montpellier.fr. 2. Department of Neurology, CHRU, Gui de Chauliac Hospital, Montpellier, France. Electronic address: pauline.malissart@gmail.com. 3. Department of Neuroradiology, University Hospital Center, Montpellier, France. Electronic address: c-dargazanli@chu-montpellier.fr. 4. Medical Information Department, University Hospital Center, Montpellier, France. Electronic address: e-nogue@chu-montpellier.fr. 5. Department of Neurology, Caremeau Hospital, Nimes, France. Electronic address: stephane.bouly@chu-nimes.fr. 6. Department of Neurology, CHRU, Gui de Chauliac Hospital, Montpellier, France; Department of Neurology, Hospital of Perpignan, France. Electronic address: n-gaillard@chu-montpellier.fr. 7. Department of Neurology, Hospital of Beziers, France. Electronic address: yassine.boukriche@ch-beziers.fr. 8. Department of Neurology, CHRU, Gui de Chauliac Hospital, Montpellier, France. Electronic address: l-corti@chu-montpellier.fr. 9. Medical Information Department, University Hospital Center, Montpellier, France. Electronic address: mc-picot@chu-montpellier.fr. 10. Department of Emergency, University Hospital Center, Montpellier, France. Electronic address: o-beaufils@chu-montpellier.fr. 11. Department of Neurology, Hospital of Narbonne, France. Electronic address: mohamed.chbicheb@ch-narbonne.fr. 12. Department of Neurology, Hospital of Perpignan, France. Electronic address: denis.sablot@ch-perpignan.fr. 13. Department of Neuroradiology, University Hospital Center, Montpellier, France. Electronic address: a-bonafe@chu-montpellier.fr. 14. Department of Neuroradiology, University Hospital Center, Montpellier, France. Electronic address: v-costalat@chu-montpellier.fr. 15. Department of Neurology, CHRU, Gui de Chauliac Hospital, Montpellier, France. Electronic address: c-arquizan@chu-montpellier.fr.
Abstract
BACKGROUND: Mechanical thrombectomy (MT) in association with intravenous thrombolysis is recommended for treatment of acute ischemic stroke (AIS), with large vessel occlusion (LVO) in the anterior circulation. Because MT is only available in comprehensive stroke centers (CSC), the challenge of stroke organization is to ensure equitable access to the fastest endovascular suite. Our aim was to evaluate the feasibility, efficacy, and safety of MT in patients initially managed in 1 CSC (mothership), compared with patients first managed in primary stroke center (PSC), and then transferred to the CSC for MT (drip-and-ship). METHODS: We retrospectively analyzed 179 consecutive patients (93 in the mothership group and 86 in the drip-and-ship group), with AIS secondary to LVO in the anterior cerebral circulation and a clinical-radiological mismatch (NIHSS ≥ 8 and DWI-ASPECT score ≥5), up to 6 hours after symptoms onset. We evaluated 3-month functional modified Rankin scale (mRS), periprocedural time management, mortality, and symptomatic intracranial haemorrhage (sICH). RESULTS: Despite significant longer process time in the drip-and-ship group, mRS ≤ 2 at 3 months (39.8% versus 44.1%, P = .562), Thrombolysis in cerebral infarction 2b-3 (85% versus 78%, P = .256), and sICH (7.0% versus 9.7%, P = .515) were similar in both group regardless of baseline clinical or radiological characteristics. After multivariate logistic regression, the predictive factors for favorable outcome were age (odds ratio [OR] -5years= 1.32, P < .001), initial NIHSS (OR -5points = 1.59, P = .010), absence of diabetes (OR = 3.35, P = .075), and the delay magnetic resonance imagining-puncture (OR -30min = 1.16, P = .048). CONCLUSIONS: Our study showed encouraging results from a regional protocol of MT comparing patients transferred from PSC or brought directly in CSC.
BACKGROUND: Mechanical thrombectomy (MT) in association with intravenous thrombolysis is recommended for treatment of acute ischemic stroke (AIS), with large vessel occlusion (LVO) in the anterior circulation. Because MT is only available in comprehensive stroke centers (CSC), the challenge of stroke organization is to ensure equitable access to the fastest endovascular suite. Our aim was to evaluate the feasibility, efficacy, and safety of MT in patients initially managed in 1 CSC (mothership), compared with patients first managed in primary stroke center (PSC), and then transferred to the CSC for MT (drip-and-ship). METHODS: We retrospectively analyzed 179 consecutive patients (93 in the mothership group and 86 in the drip-and-ship group), with AIS secondary to LVO in the anterior cerebral circulation and a clinical-radiological mismatch (NIHSS ≥ 8 and DWI-ASPECT score ≥5), up to 6 hours after symptoms onset. We evaluated 3-month functional modified Rankin scale (mRS), periprocedural time management, mortality, and symptomatic intracranial haemorrhage (sICH). RESULTS: Despite significant longer process time in the drip-and-ship group, mRS ≤ 2 at 3 months (39.8% versus 44.1%, P = .562), Thrombolysis in cerebral infarction 2b-3 (85% versus 78%, P = .256), and sICH (7.0% versus 9.7%, P = .515) were similar in both group regardless of baseline clinical or radiological characteristics. After multivariate logistic regression, the predictive factors for favorable outcome were age (odds ratio [OR] -5years= 1.32, P < .001), initial NIHSS (OR -5points = 1.59, P = .010), absence of diabetes (OR = 3.35, P = .075), and the delay magnetic resonance imagining-puncture (OR -30min = 1.16, P = .048). CONCLUSIONS: Our study showed encouraging results from a regional protocol of MT comparing patients transferred from PSC or brought directly in CSC.
Authors: A Benali; M Moynier; C Dargazanli; J Deverdun; F Cagnazzo; I Mourand; A Bonafe; C Arquizan; I Derraz; N Menjot de Champfleur; F Molino; A Ducros; E Le Bars; V Costalat Journal: AJNR Am J Neuroradiol Date: 2021-01-21 Impact factor: 3.825